Feeds:
Posts
Comments

Posts Tagged ‘Pfizer’

*****
TODAY’S NEWS

Sanofi taking a heavy dice-roll on Multaq: 11,000-patient trial on expanded use.

A glimpse into Merck‘s late-stage pipeline. Very diverse group of molecules and conditions. Here’s an interesting little extra on the cholesterol drug.

FDA launches 1-800-TATTLE: The FDA is asking healthcare professionals to keep an eye out for violative promotion and to call 1-877-RX-DDMAC or emailing badad@fda.com when they see itmore

Pfizer: NYC layoffs and relos, plus selling a midtown building. And, late-breaking, Takeda also embarking on major cuts.

The VA about to tighten the rules on drug sales rep interactions. Part of a nationwide trend.

RECOMMENDED

Management Training. The Impactiviti network can help you with all your needs for training managers, finding the optimal suppliers for you. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

So…who’s been doing the best Social Media in Pharma? The new Dosie Award winners were announced live at the BDI Social Communications in Healthcare event yesterday.

JUST FOR FUN

Sunsets. Nice.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Advertisements

Read Full Post »

As more and more pharmaceutical companies dip their toes into social media, one of the issues that surfaces regularly is this: do you put someONE in charge of a blog and/or Twitter account, or do you make it more anonymous? Or something else?

Let’s discuss this. I’ll put out my thoughts; add yours in the comments.

I’ve always advocated that pharma companies should use social networks to humanize their companies, which means employing human faces and voices – having real, authentic, and effective communicators working these channels. People. Folks you can relate to meet, meet at a conference, carry on backchannel discussions with, etc.

J&J has been very effective with this; Marc Monseau has served effectively as the “voice” of J&J in the socialsphere. Recently, Pfizer (@pfizer_news on Twitter) has updated its Twitter account to include a face and a name – Jennifer Kokell, self-identified as tweeting from Global Corporate Media Relations in NYC. Jennifer works with Ray Kerins, who has been aggressively shaking up the Communications practices at Pfizer, including a healthy push into social media.

But the question comes up – what if a company’s social media presence is too dependent on one person? And here the fine line must be walked – on the one hand, social media is all about individuals and personality and dialogue between people – but companies are not one person. And people move on.

By and large, people don’t want another nameless, faceless monolithic channel in social media – some unnamed drone churning out one-way communications in the name of “the company” who has about as much relational value as a dead fish. So – how to strike the balance?

Here’s one idea for larger companies – have a team presence for your blog and Twitter account. Multiple people – say, 3 or 4 – who contribute posts and tweets about a cross-section of the company’s activities. These would be real people with names, pictures, and off-line appearances – but the team approach would reflect the reality that a company IS made up of diverse individuals, and would also make the social media presence less dependent on a solo individual (reflecting the hit-by-a-bus reality of the non-expendable individual). While J&J’s social presence is spearheaded by Marc Monseau, their corporate blog actually has other contributing authors.

That would be one approach for an “official” social media presence. What about “unofficial” social media representatives? I like what is happening at Novartis, where various individuals such as Brad Pendergraph, Colin Foster, Mark Davis, Erik Hawkinson, Ben Atkins and others tweet as professional and accessible human beings who work at Novartis (thus achieving some humanizing of the company) but who have a unique presence reflecting their personal interests and professional perspectives. In fact, with Novartis, the “unofficial” social media presence has far outstripped progress on its “official” corporate social media footprint.

We’re all still on the learning curve with this stuff and companies are experimenting and evolving. What’s your take? One? Many? None? How can a company project humanity and authenticity without too much solo-representative risk?

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Download free e-book: Getting Started with Social Networking.

Read Full Post »

*****

TODAY’S NEWS

Forbes: Pfizer‘s history of buying pipeline lemons. This does only tell one side of the story, however – Pfizer has also acquired some pretty major hits.

Speaking of flops, a couple of major experimental drugs aren’t looking so hot these days.

FDA taking another look at some bone drugs, in relation to hip fractures – There have long been safety questions — and lawsuits — over whether bone-building drugs like Merck’s Fosamax can actually increase the chance of femur fractures. Today, the FDA said it was going to take another look at the safety issuesmore

Did J&J plan to break the rules with Risperdal? Business Week reports. Plus, Shire gets a “fourfecta” warning letter from the FDA on one marketing promotion.

RECOMMENDED

Meetings/Events/Launches – Looking for creative and successful providers who can help make your off-site events a hit? We’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Nine Simple Steps to Getting Started in Social Media. Good stuff from Dose of Digital blog. For a practical guide on how YOU (as an individual) can put social networking to use building your own Opportunity Network, download my free e-book on that subject.

JUST FOR FUN

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

***

Read Full Post »

*****

TODAY’S NEWS

New experimental RA/Lupus drug suspended after patient deaths – Swiss drugmaker Roche Holding AG and U.S. biotechnology company Biogen Idec are suspending rheumatoid arthritis and lupus treatment ocrelizumab after it caused deaths, casting doubt over the drug’s futuremore

So, what about Amylin‘s Byetta? The pundits are dueling as potential once-a-week version approval draws near…

An interesting background story on Pfizer‘s expensive oncology “miracle” drug Sutent.

RECOMMENDED

Training new (or experienced) brand managers? – We’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

A “trifecta” social media approach – Novartis sponsors a community, Twitter account, and Facebook Fan Page for Cystic Fibrosis patients. How are they doing? An Impactiviti review.

JUST FOR FUN

Top 10 Most Stupid Inventions. No disagreement here!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

***

Read Full Post »

*****

TODAY’S NEWS

If Shire were in Olympics, they’d now be on the speed skating short track – Shire has been boosted by the news that regulators in the USA will give a quicker review to the firm’s Fabry disease drug Replagal. The company has received fast-track designation from the US Food and Drug Admininstration for Replagal (agalsidase alfa), its enzyme replacement therapy for Fabry disease. The drug has also been available under an early access programme in the USA since December following the temporary shutdown of a Genzyme manufacturing plant which caused the shortage of the latter’s Fabrazyme (agalsidase beta)more

Pfizer gets the FDA go-ahead for updated vaccine – Pfizer said Wednesday the Food and Drug Administration has approved an updated version of its best-selling infection vaccine for infants and children. Prevnar 13 is intended to reduce the risk of infection by 13 strains of pneumococcal disease in children 5 years old and younger. The disease causes ear infections, meningitis and pneumoniamore However, no standing ovation for experimental osteoporosis drug.

Scorecarding which drugs caused the most adverse events. I’m guessing Too Many Donuts trumps all of them combined…

RECOMMENDED

Speaker training – Looking for programs to help your managers, executives, and sales representatives present like pros? We’ve got the providers you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for vendor recommendations.

PLUS

The Pharma and Healthcare Wiki – one year old and full of value! My friend and co-conspirator Jon Richman launched this very valuable (and quite comprehensive) collection of social media resources and examples a year ago, taking off on my initial SocialRx page and making a great resource for the industry. Need to know what’s going on in eMarketing/eHealth/Social Media? Go there!

JUST FOR FUN

The world’s 18 strangest airports. I’ll say this for my home airport, Newark – you do get to see some awfully strange sights while shuffling for hours in the security lines…

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS

Big approval news for Gilead Sciences Gilead Sciences Inc., the world’s largest maker of HIV treatments, won U.S. approval of an inhaled antibiotic for lung infections in cystic fibrosis patients. The Food and Drug Administration cleared sales of the medicine, given the brand name Cayston, the company said today in a statement. Outside advisers to the FDA backed the product’s safety and effectiveness in a 15-2 vote on Dec. 10more

What is the future of “personalized medicine”? Probably, it’ll look a lot like this (encouraging story from NY Times). Plus, in a cooperative effort, Eli Lilly, Merck and Pfizer have formed an independent, not-for-profit company Asian Cancer Research Group (ACRG) to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asiamore

Of course, in this industry, there is often a mix of good news and bad – and “bad” usually means bad behavior by people who love dollars above sense: lack of openness at AZ?; secret tapes and GSK (plus, a “fixer” who spiked research?); research fraud by rogue doc; kickbacks and J&J; risk of depression assessment and Eli Lilly (are you alive? then you’re at risk!!!). Reminds me of some prior posts on the Gold-in Rule

Novartis looking to expand even more at East Hanover campus. Including themed food venues!

RECOMMENDED

Marketing Training – Looking for resources for training brand marketing professionals? We know the providers you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for vendor recommendations.

PLUS

I’m feeling much safer now. FDA finally comes out against “ear candling“! Next up, perhaps – a prohibition of USB-to-nasal-passage uploads??

JUST FOR FUN

Delightful (and BIG) pictures from Vancouver Olympics. Love the colors in the very first one. From Boston.com’s very nice The Big Picture section.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

TODAY’S NEWS

Pfizer and Merck top sales forces, and overcharging New York.

Harrison Ford and a movie about a biotech company. Not the next Avatar with ticket sales, apparently.

Big Pharma’s messy pipeline.

RECOMMENDED

Simulations for training – “Live” simulations or eLearning experiences – our preferred partners can provide what you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Corporate cultures: Some for Fun and Fun for Some – in which I take on the Grinch and Harvard Business Review! :>}

JUST FOR FUN

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Older Posts »